Shots:
- AbbVie & Simcere Zaiming (subsidiary Simcere Pharma) have signed an option to license agreement for developing SIM0500, being assessed in P-I for r/r multiple myeloma (MM) in the US & China
- As per the terms, Simcere will get an upfront, up to $1.055B option fees & milestones plus net-sales-based tiered royalties outside Greater China while AbbVie is entitled for tiered royalties in Greater China
- SIM0500 (GPRC5D, BCMA & CD3 targeting TsAb) is developed by Simcere’s T-cell engager polyspecific Ab tech, consisting of a low-affinity CD3 arm & binding sites for GPRC5D & BCMA. It has depicted strong T-cell-mediated cytotoxicity against MM cells through a combination of antitumor mechanisms
Ref: AbbVie | Image: AbbVie & Simcere
Related News:- AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
